Schizoaffective disorder

Summary

Schizoaffective disorder (MONDO:0005487) is a disease with 5 cohort genes (8 GWAS associations across 4 studies) and 551 clinical trials. Top therapeutic interventions include ziprasidone, olanzapine, and quetiapine.

At a glance

• Cohort genes: 5
• GWAS associations: 8
• Clinical trials: 551

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schizoaffective disorder
Mondo ID	MONDO:0005487
EFO	EFO:0005411
DOID	DOID:5418
ICD-11	106339515
NCIT	C94378
UMLS	C0036337
MedGen	11334
Is cancer (heuristic)	no

Data availability: 8 GWAS associations (4 studies).

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › schizoaffective disorder

Related subtypes (7): schizophreniform disorder, alcoholic psychosis, delusional disorder, substance-induced psychosis, schizophrenia, methamphetamine-induced psychosis, postpartum psychosis

Subtypes (2): schizoaffective bipolar disorder, schizoaffective depressive disorder

Genetics & variants

GWAS landscape

8 GWAS associations across 4 studies. Top hits map to 6 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs4721295	6e-10	MAD1L1	?
rs17693963	2e-09	GPR89P - RSL24D1P1	?
rs776877	3e-09	GALNT13	?	1.39
rs6703335	4e-09	SDCCAG8	?
rs2710323	3e-08	ITIH1	?
rs2077586	4e-08	EMX1	?
rs6558872	5e-08	CSMD1	?
rs75608493	5e-08	LINC01741 - SEC16B	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST009283	Bigdeli TB	2019	6,152	3,918	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry.
GCST90473261	UK Biobank Whole-Genome Sequencing Consortium	2025	316	458,124	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90726762	Kim HI	2026	138	43,888	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST002254	Sleiman P	2013	0	0	GWAS meta analysis identifies TSNARE1 as a novel Schizophrenia / Bipolar susceptibility locus.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	8
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	7
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4721295	7	1997034	T>G	0.378	intron_variant	MAD1L1	6e-10	Tier 4: intronic/intergenic
rs17693963	6	27742386	A>C,G	0.096	intron_variant	GPR89P - RSL24D1P1	2e-09	Tier 4: intronic/intergenic
rs776877	2	153941017	A>C,G	0.05	intron_variant	GALNT13	3e-09	Tier 4: intronic/intergenic
rs6703335	1	243445665	A>G	0.438	intron_variant	SDCCAG8	4e-09	Tier 4: intronic/intergenic
rs2710323	3	52781889	T>A,C,G	0.466	intron_variant	ITIH1	3e-08	Tier 4: intronic/intergenic
rs2077586	2	72934422	A>G	0.05	3_prime_UTR_variant	EMX1	4e-08	Tier 2: splice/UTR
rs6558872	8	4380617	G>A,C	0.429	intron_variant	CSMD1	5e-08	Tier 4: intronic/intergenic
rs75608493	1	177796886	C>G,T	0.05	intron_variant	LINC01741 - SEC16B	5e-08	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SDCCAG8	Orphanet:110	Bardet-Biedl syndrome
SDCCAG8	Orphanet:3156	Senior-Loken syndrome

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SDCCAG8	HGNC:10671	ENSG00000054282	Q86SQ7	Serologically defined colon cancer antigen 8	gwas
CSMD1	HGNC:14026	ENSG00000183117	Q96PZ7	CUB and sushi domain-containing protein 1	gwas
GALNT13	HGNC:23242	ENSG00000144278	Q8IUC8	Polypeptide N-acetylgalactosaminyltransferase 13	gwas
ITIH1	HGNC:6166	ENSG00000055957	P19827	Inter-alpha-trypsin inhibitor heavy chain H1	gwas
MAD1L1	HGNC:6762	ENSG00000002822	Q9Y6D9	Mitotic spindle assembly checkpoint protein MAD1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SDCCAG8	Serologically defined colon cancer antigen 8	Plays a role in the establishment of cell polarity and epithelial lumen formation.
CSMD1	CUB and sushi domain-containing protein 1	Potential suppressor of squamous cell carcinomas.
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine (GalNAc) residue from UDP-GalNAc to a serine or threonine residue on the protein receptor.
ITIH1	Inter-alpha-trypsin inhibitor heavy chain H1	May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are es…
MAD1L1	Mitotic spindle assembly checkpoint protein MAD1	Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Complement	1	53.6×	0.056
Enzyme (other)	1	2.4×	0.530
Other/Unknown	3	1.1×	0.608

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SDCCAG8	Other/Unknown	no		SDCCAG8
CSMD1	Complement	yes		Sushi_SCR_CCP_dom, CUB_dom, Sperma_CUB_dom_sf
GALNT13	Enzyme (other)	yes	2.4.1.41	Ricin_B_lectin, Glyco_trans_2-like, Nucleotide-diphossugar_trans
ITIH1	Other/Unknown	no		VWF_A, ITI_HC_C, VIT
MAD1L1	Other/Unknown	no		Mad1

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
calcaneal tendon	1
corpus callosum	1
thyroid gland	1
Brodmann (1909) area 23	1
middle temporal gyrus	1
primary visual cortex	1
cerebellar cortex	1
cerebellar hemisphere	1
cerebellum	1
liver	1
male germ line stem cell (sensu Vertebrata) in testis	1
right lobe of liver	1
left testis	1
right testis	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SDCCAG8	134	ubiquitous	marker	corpus callosum, calcaneal tendon, thyroid gland
CSMD1	179	broad	marker	Brodmann (1909) area 23, middle temporal gyrus, primary visual cortex
GALNT13	184	broad	marker	cerebellar cortex, cerebellar hemisphere, cerebellum
ITIH1	154	tissue_specific	marker	right lobe of liver, liver, male germ line stem cell (sensu Vertebrata) in testis
MAD1L1	137	ubiquitous	marker	sural nerve, right testis, left testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MAD1L1	2,947
SDCCAG8	1,837
CSMD1	1,577
ITIH1	1,543
GALNT13	977

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MAD1L1	Q9Y6D9	5
ITIH1	P19827	2
CSMD1	Q96PZ7	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
GALNT13	Q8IUC8	93.06
SDCCAG8	Q86SQ7	78.67

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 31. Enrichment computed across 5 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Mitotic Prometaphase	2	46.1×	0.011	SDCCAG8, MAD1L1
M Phase	2	44.0×	0.011	SDCCAG8, MAD1L1
Cell Cycle, Mitotic	2	32.1×	0.013	SDCCAG8, MAD1L1
Cell Cycle	2	24.0×	0.018	SDCCAG8, MAD1L1
Centrosome maturation	1	84.6×	0.044	SDCCAG8
Amplification of signal from the kinetochores	1	65.6×	0.044	MAD1L1
O-linked glycosylation of mucins	1	61.4×	0.044	GALNT13
Loss of Nlp from mitotic centrosomes	1	52.9×	0.044	SDCCAG8
Loss of proteins required for interphase microtubule organization from the centrosome	1	52.9×	0.044	SDCCAG8
Mitotic Spindle Checkpoint	1	52.9×	0.044	MAD1L1
AURKA Activation by TPX2	1	50.8×	0.044	SDCCAG8
Recruitment of mitotic centrosome proteins and complexes	1	45.3×	0.044	SDCCAG8
Regulation of PLK1 Activity at G2/M Transition	1	42.3×	0.044	SDCCAG8
Mitotic G2-G2/M phases	1	42.3×	0.044	SDCCAG8
G2/M Transition	1	42.3×	0.044	SDCCAG8
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	1	38.8×	0.044	MAD1L1
Recruitment of NuMA to mitotic centrosomes	1	38.8×	0.044	SDCCAG8
Anchoring of the basal body to the plasma membrane	1	37.7×	0.044	SDCCAG8
Cilium Assembly	1	36.2×	0.044	SDCCAG8
Mitotic Metaphase and Anaphase	1	32.3×	0.044	MAD1L1
Mitotic Anaphase	1	32.3×	0.044	MAD1L1
EML4 and NUDC in mitotic spindle formation	1	30.9×	0.044	MAD1L1
Cell Cycle Checkpoints	1	29.5×	0.044	MAD1L1
Resolution of Sister Chromatid Cohesion	1	28.8×	0.044	MAD1L1
RHO GTPases Activate Formins	1	25.9×	0.047	MAD1L1
RHO GTPase Effectors	1	22.7×	0.051	MAD1L1
Organelle biogenesis and maintenance	1	22.0×	0.051	SDCCAG8
Separation of Sister Chromatids	1	20.2×	0.054	MAD1L1
Signaling by Rho GTPases	1	11.4×	0.090	MAD1L1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1	11.2×	0.090	MAD1L1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
oviduct epithelium development	1	1123.5×	0.010	CSMD1
deactivation of mitotic spindle assembly checkpoint	1	1123.5×	0.010	MAD1L1
mammary gland branching involved in pregnancy	1	842.6×	0.010	CSMD1
regulation of metaphase plate congression	1	674.1×	0.010	MAD1L1
hyaluronan metabolic process	1	421.3×	0.011	ITIH1
tube formation	1	421.3×	0.011	SDCCAG8
conditioned place preference	1	337.0×	0.011	CSMD1
positive regulation of mitotic cell cycle spindle assembly checkpoint	1	306.4×	0.011	MAD1L1
microtubule organizing center organization	1	280.9×	0.011	SDCCAG8
startle response	1	224.7×	0.012	CSMD1
attachment of mitotic spindle microtubules to kinetochore	1	210.7×	0.012	MAD1L1
female gonad development	1	160.5×	0.014	CSMD1
regulation of cilium assembly	1	120.4×	0.017	SDCCAG8
mitotic spindle assembly checkpoint signaling	1	112.3×	0.017	MAD1L1
protein O-linked glycosylation via N-acetylgalactosamine	1	86.4×	0.020	GALNT13
establishment of cell polarity	1	76.6×	0.020	SDCCAG8
cell projection organization	1	74.9×	0.020	SDCCAG8
centrosome cycle	1	67.4×	0.020	SDCCAG8
thymus development	1	67.4×	0.020	MAD1L1
negative regulation of T cell proliferation	1	66.1×	0.020	MAD1L1
protein O-linked glycosylation	1	44.9×	0.028	GALNT13
memory	1	36.6×	0.033	CSMD1
male gonad development	1	31.2×	0.037	CSMD1
neuron migration	1	26.8×	0.041	SDCCAG8
glucose homeostasis	1	26.1×	0.041	CSMD1
gene expression	1	16.0×	0.063	CSMD1
cell division	1	9.2×	0.104	MAD1L1

Therapeutics

Drugs indicated for this disease

10 approved, 16 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aripiprazole	Approved (phase 4)
Brexpiprazole	Approved (phase 4)
Clozapine	Approved (phase 4)
Haloperidol	Approved (phase 4)
Olanzapine	Approved (phase 4)
Paliperidone	Approved (phase 4)
Paliperidone Palmitate	Approved (phase 4)
Quetiapine	Approved (phase 4)
Risperidone	Approved (phase 4)
Ziprasidone	Approved (phase 4)
(D)-Serine	Phase 3 (in late-stage trials)
Amantadine	Phase 3 (in late-stage trials)
Aspirin	Phase 3 (in late-stage trials)
Bexarotene	Phase 3 (in late-stage trials)
Cannabidiol	Phase 3 (in late-stage trials)
Fenretinide	Phase 3 (in late-stage trials)
Icosapent	Phase 3 (in late-stage trials)
Lorazepam	Phase 3 (in late-stage trials)
Lurasidone	Phase 3 (in late-stage trials)
Metformin	Phase 3 (in late-stage trials)
Minocycline	Phase 3 (in late-stage trials)
Pipamperone	Phase 3 (in late-stage trials)
Pramipexole	Phase 3 (in late-stage trials)
Raloxifene	Phase 3 (in late-stage trials)
Sulforaphane	Phase 3 (in late-stage trials)
Zonisamide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bifeprunox, Brilaroxazine, Cholecalciferol, Cycloserine, Dextrose, Estradiol, Galantamine, Glycine, Memantine, Pregnenolone Succinate, Serine, Valacyclovir, Varenicline.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5

Druggability breadth: 1 of 5 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SDCCAG8	0	0
CSMD1	0	0
GALNT13	0	0
ITIH1	0	0
MAD1L1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
GALNT13	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
GALNT13	2.4.1.41	polypeptide N-acetylgalactosaminyltransferase

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	CSMD1
D	Druggable family + AlphaFold only, no drug	1	GALNT13
E	Difficult family or no structure, no drug	3	SDCCAG8, ITIH1, MAD1L1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SDCCAG8	0	—
CSMD1	0	—
GALNT13	1	—
ITIH1	0	—
MAD1L1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 551.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	284
PHASE4	119
PHASE3	49
PHASE2	47
PHASE1	33
PHASE1/PHASE2	9
PHASE2/PHASE3	7
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02639702	PHASE4	RECRUITING	Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
NCT03495024	PHASE4	RECRUITING	Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
NCT04580134	PHASE4	RECRUITING	CLOZAPINE Response in Biotype-1
NCT05208190	PHASE4	RECRUITING	Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT06562608	PHASE4	RECRUITING	Anticholinergic Deprescription in Schizophrenia
NCT06740890	PHASE4	RECRUITING	Exercise and Olanzapine-samidorphan
NCT07105111	PHASE4	RECRUITING	A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00177580	PHASE4	COMPLETED	Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
NCT00190749	PHASE4	COMPLETED	Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00202293	PHASE4	COMPLETED	Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
NCT00206102	PHASE4	COMPLETED	A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
NCT00208143	PHASE4	COMPLETED	Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
NCT00208169	PHASE4	COMPLETED	Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00215579	PHASE4	COMPLETED	Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00222794	PHASE4	COMPLETED	A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
NCT00224822	PHASE4	COMPLETED	The Effects of Aripiprazole on Patients With Metabolic Syndrome
NCT00231335	PHASE4	COMPLETED	Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
NCT00246259	PHASE4	COMPLETED	A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00253110	PHASE4	COMPLETED	A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
NCT00269919	PHASE4	COMPLETED	An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00303602	PHASE4	COMPLETED	Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
NCT00304655	PHASE4	COMPLETED	Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
NCT00306475	PHASE4	COMPLETED	Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
NCT00313391	PHASE4	COMPLETED	Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
NCT00314327	PHASE4	TERMINATED	Optimizing Response in Psychosis Study
NCT00320697	PHASE4	COMPLETED	Smoking Relapse Prevention in Schizophrenia
NCT00320723	PHASE4	COMPLETED	Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia
NCT00320736	PHASE4	COMPLETED	Galantamine for Cognition in People With Schizophrenia
NCT00325689	PHASE4	COMPLETED	Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00330863	PHASE4	COMPLETED	Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00337662	PHASE4	COMPLETED	Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ZIPRASIDONE	4	45
OLANZAPINE	4	16
QUETIAPINE	4	11
RISPERIDONE	4	11
ARIPIPRAZOLE	4	10
VARENICLINE	4	10
CLOZAPINE	4	9
RALOXIFENE	4	9
LURASIDONE	4	7
BUPROPION	4	6
HALOPERIDOL	4	4
MODAFINIL	4	4
PALIPERIDONE PALMITATE	4	4
AMANTADINE	4	3
AMISULPRIDE	4	3
ATOMOXETINE	4	3
CHLORPROMAZINE	4	3
GALANTAMINE	4	3
NALTREXONE	4	3
PALIPERIDONE	4	3
ASENAPINE	4	2
BREXPIPRAZOLE	4	2
CANNABIDIOL	4	2
CYCLOSERINE	4	2
GLYCINE	4	2
HALOPERIDOL DECANOATE	4	2
MEMANTINE	4	2
METFORMIN	4	2
MINOCYCLINE	4	2
PERPHENAZINE	4	2